ClinicalTrials.gg
RecruitingNCT05772637CUBS-MSUpdated Mar 5, 2026

Clinical and Urodynamic Assessment of Bladder Sensation in Multiple Sclerosis

An interventional study of Repeated cystometries with bladder sensations assessment in Overactive Bladder, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-03-05.

Sponsored by Assistance Publique - Hôpitaux de Paris · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Feb 2024; still recruiting 2 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
113
Allocation
Not applicable
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 53 studies in Urinary Bladder, Overactive with a site in France — 6 open to participants now, 6 under way, none of them phase 3. Urinary Bladder, Overactive · France.

Planned enrollment
28th of 40
113 · median 267
Started
2024
with 4 others
No phase
11 of 53
5 open now
Registered
46th of 53
by date
Lead sponsor
4 of 53
Assistance Publique - Hôpitaux de Paris

Among the 53 studies in Urinary Bladder, Overactive with a site in France, this one is the 28th largest by planned enrollment of the 40 interventional ones that give a count, is one of 5 that started in 2024, is one of 11 with no phase, and was the 46th registered.

Urinary Bladder, Overactive

861 studies on the registry are indexed under Urinary Bladder, Overactive; 128 are open to participants now.

Browse Urinary Bladder, Overactive studies →

Open to participants now

6 of the 53 studies in Urinary Bladder, Overactive with a site in France are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 75 Urinary Bladder, Overactive studies recruiting now, 45 (60%) set no upper age limit and 16 (21%) stop at 75 or younger; 7 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies in Urinary Bladder, Overactive with a site in France, or all of them as a file.
02

Study summary

The aim of the study is to assess the association between bladder sensations progression during bladder filling and severity of Overactive bladder (OAB) in patients with multiple sclerosis.

Read the detailed description

Lower urinary tract symptoms (LUTS) are frequent in central nervous system disorders especially in patients with multiple sclerosis (PwMS). Prevalence of LUTS is important (32 to 96.8%) and increases with multiple sclerosis (MS) duration and the severity of the neurological deficiencies and disabilities. Overactive bladder (OAB) with urgency, frequency, urgency urinary incontinence, is the most common symptom, reported by 37-99% of the PwMS. Voiding difficulties are less common, from 6 to 49%, and usually appear later with the course of the disease.

Urodynamics is a useful test recommended to understand the mechanism of bladder dysfunction, and look for risk factors of upper tract damage.

Detrusor overactivity is the most reported mechanism of overactive bladder, and describes the occurrence of uninhibited contractions of the detrusor during bladder filling. But abnormal bladder sensations, with increased or decreased sensations, have also been described. The prevalence of these abnormalities is not well described, however, in the absence of detrusor overactivity, abnormal afferent information (i.e., abnormal bladder sensations) is the plausible mechanism involved in urinary disorders.

The assessment of bladder sensations is still a poorly explored field. Bladder diary can be used for the collection of the intensity of need to void with a Likert scale or numerical scale.

During cystometry, it is recommended to collect different bladder sensations: first sensation of filling, first desire to void, strong desire to void, urgent desire to void. However, it has been described that bladder sensations progress in 8 to 9 different levels of intensity in healthy subjects.

The aim of the study is to assess the association between bladder sensations progression during bladder filling and severity of OAB in patients with multiple sclerosis.

03

Conditions studied

  • Overactive Bladder

Keywords

  • overactive bladder
  • multiple sclerosis
  • bladder sensations
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18
  • MS according to the 2017 Mac Donald diagnostic criteria
  • Bladder disorders supposedly related to MS
  • Indication to perform urodynamics
  • No current medication for bladder disorders
  • Able to understand and right in French
  • Affiliated to the "Securite sociale" or "Couverture Medicale Universelle (CMU)", or equivalent organism.

Exclusion criteria

Exclusion criteria:

  • Legal protection
  • Pregnancy or breastfeeding mother
  • MS relapse during the past month
  • Other associated neurological disease
  • Genuine stress incontinence related to postpartum
  • Treatment with antimuscarinics, alpha blockers, beta3 adrenergic, or tibial nerve stimulation in the past 15 days, or with botulinic toxin injection in the past 6 months
  • Previous lower urinary tract surgery
  • Inability to use the analogic device due to motor, sensory or ataxic disabilities
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
113 participants (estimated)

Study arms

  • Experimental
    MS Patient with Bladder disorders

    Procedure: Repeated cystometries with bladder sensations assessment

Interventions

  • ProcedureRepeated cystometries with bladder sensations assessment

    A second cystometry will be performed to assess bladder sensations reliability. A third cystometry with cognitive task (STROOP test) at the same time will be performed to assess the impact of distractive attentional task on bladder sensations

06

What researchers measure

Primary outcomes

  1. bladder sensation ( area under the sensation-capacity curve (AUC))

    The areas under the sensation-capacity curve (AUC) will be calculated for individual participants using the trapezoidal rule for specific capacity ranges.

    Time frame: Day 1

Secondary outcomes

  1. bladder sensitivity

    Bladder sensitivity assessed by the number of steps in the evolution of the need to urinate reported by the patient (number of times the cursor of the analogical scale is moved), during the filling.

    Time frame: Day 1

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2024 (actual). Primary completion is estimated for Feb 2027, 36 months after the start.

Of 135 non-industry interventional studies with no phase under Urinary Bladder, Overactive, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 40. This study's planned 36 months is above that.

Counting every sponsor, half of 176 studies reached it within 19 months; a quarter within 10 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 22, 2023
First posted
Mar 16, 2023
StartActual
Feb 14, 2024
Primary completionEst.
Feb 14, 2027
CompletionEst.
Feb 14, 2027
Last update
Mar 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05772637
Responsible party
Sponsor
First posted
Mar 16, 2023
Start date
Feb 14, 2024
Primary completion
Feb 14, 2027 (estimated)
Completion
Feb 14, 2027 (estimated)
Last update
Mar 5, 2026

Study contacts

Claire Hentzen, MD
Contact
claire.hentzen@aphp.fr
0156017500 ext. +33
Gérard AMARENCO, MD, PhD
Contact
gerard.amarenco@aphp.fr
0156017500 ext. +33

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion